The Prevalence of Cancer in Patients with Multiple Sclerosis (MS) who were Under Treatment with Natalizumab (Tysabri): A Systematic Review and Meta ‑Analysis
Conclusions: The main finding of this systematic review and metaanalysis is that the pooled prevalence of cancer in subjects who suffer from MS and received natalizumab was 2%.
Source: International Journal of Preventive Medicine - Category: International Medicine & Public Health Source Type: research
More News: Basal Cell Carcinoma | Cancer | Cancer & Oncology | Carcinoma | International Medicine & Public Health | Multiple Sclerosis | Science | Skin Cancer | Study | Tysabri